Mucosal melanoma of the head and neck

Kanetaka,Sayaka; Tsukuda,Mamoru; Takahashi,Masahiro; Komatsu,Masanori; Niho,Tatsuo; Horiuchi,Choichi; Matsuda,Hideki

doi:10.3892/etm.2011.313

Mucosal melanoma of the head and neck

Authors:
- Sayaka Kanetaka
- Mamoru Tsukuda
- Masahiro Takahashi
- Masanori Komatsu
- Tatsuo Niho
- Choichi Horiuchi
- Hideki Matsuda
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan
Published online on: June 30, 2011 https://doi.org/10.3892/etm.2011.313
Pages: 907-910

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mucosal melanoma of the head and neck (MMHN) is a rare malignant tumor associated with a poor prognosis. A retrospective study of case records of patients treated at our department between 1992 and 2010 was carried out. Thirteen patients were enrolled. The median age of the patients (3 males and 10 females) was 61 years (range 39-78). The median follow-up period was 48 months (range 10-115). Two common primary sites were the nasal cavity (8 cases) and sinonasal complex (5 cases). Ten patients (77%) received curative surgery. Chemotherapy was administered to 10 patients. In addition, lymphokine-activated killer (LAK) cell therapy was administered to 7 patients as adjunctive immunotherapy after the initial treatment course. The overall 5-year, cause-specific survival rate was 56%. Patients who received adjunctive LAK cell therapy had a survival rate of 67% at 5 years, while patients who did not receive adjunctive LAK cell treatment had a survival rate of 33%. MMHN is associated with a poor survival rate. The most common cause of death is distant metastasis. Surgery, radiotherapy and chemotherapy are common strategies for MMHN, but the control of metastasis is difficult. The use of immunotherapy remains uncommon for MMHN. However, from the viewpoint of a systemic disease, due to its high rate of metastases, immunotherapy using LAK cell treatment may contribute to the improvement of prognosis in patients with MMHN.

View Figures

View References

1.	Ballantyne AJ: Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 120:425–431. 1970. View Article : Google Scholar : PubMed/NCBI
2.	Tsukuda M, Mochimatsu I, Sakumoto M, et al: The synergistic effects of interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor-associated lymphocytes. Biotherapy. 6:167–174. 1993. View Article : Google Scholar : PubMed/NCBI
3.	Tsukuda M, Mochimatsu I, Sakumoto M, et al: Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy. 6:155–161. 1993. View Article : Google Scholar : PubMed/NCBI
4.	Grimm EA, Mazumder A, Zhang HZ, et al: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 155:1823–1841. 1982. View Article : Google Scholar
5.	Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 85:622–632. 1993. View Article : Google Scholar
6.	Manolidis S and Donald PJ: Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 80:1373–1386. 1997. View Article : Google Scholar : PubMed/NCBI
7.	Douglas CM, Malik T, Swindell R, et al: Mucosal melanoma of the head and neck: radiotherapy or surgery? J Otolaryngol Head Neck Surg. 39:385–392. 2010.
8.	Omura K, Takemiya S, Shimada F, et al: Malignant mucosal melanomas of the head and neck – collective review from six cancer hospitals. Gan No Rinsho. 32:1511–1518. 1986.
9.	Wada H, Nemoto K, Ogawa Y, et al: A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys. 59:495–500. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Conley JJ: Melanomas of the mucous membrane of the head and neck. Laryngoscope. 99:1248–1254. 1989. View Article : Google Scholar : PubMed/NCBI
11.	Saito H, Hozawa J and Yamagami M: Statistical analysis of malignant melanoma of nasal cavity and paranasal sinuses in Japan. Nippon Jibiinkoka Gakkai Kaiho. 86:139–143. 1983. View Article : Google Scholar : PubMed/NCBI
12.	Ishihara K, Yamazaki N and Asano K: Chemotherapy of malignant melanoma. Gan To Kagaku Ryoho. 20:1287–1292. 1993.
13.	Penel N, Mallet Y, Mirabel X, et al: Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope. 116:993–995. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Moreno MA, Roberts DB, Kupferman ME, et al: Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer. 116:2215–2223. 2010.PubMed/NCBI
15.	Mizoe JE, Tsujii H, Kamada T, et al: Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 60:358–364. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Temam S, Mamelle G, Marandas P, et al: Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 103:313–319. 2005. View Article : Google Scholar
17.	Zenda S, Kawashima M, Nishio T, et al: Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys. Oct 13–2010.(E-pub ahead of print).
18.	Trotti A and Peters LJ: Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol. 9:246–250. 1993.PubMed/NCBI
19.	Gavriel H, McArthur G, Sizeland A and Henderson M: Review: mucosal melanoma of the head and neck. Melanoma Res. April 30–2011.(E-pub ahead of print).
20.	Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 6(Suppl 1): 11–14. 2000.PubMed/NCBI
21.	Baba T, Sato-Matsushita M, Kanamoto A, et al: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med. 8:842010.PubMed/NCBI
22.	Rosenberg SA, Restifo NP, Yang JC, et al: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI